


PHARMACEUTICAL 2017

## TENAX THERAPEUTICS INC. Rank 33 of 313







PHARMACEUTICAL 2017

## RealRate

TENAX THERAPEUTICS INC. Rank 33 of 313

The relative strengths and weaknesses of TENAX THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of TENAX THERAPEUTICS INC. compared to the market average is the variable Other Compr. Net Income, increasing the Economic Capital Ratio by 1,207% points. The greatest weakness of TENAX THERAPEUTICS INC. is the variable Revenues, reducing the Economic Capital Ratio by 467% points.

The company's Economic Capital Ratio, given in the ranking table, is 126%, being 543% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	13,628
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,199
Liabilities, Non-Current	0
Other Assets	9,693
Other Compr. Net Income	87,737
Other Expenses	25,303
Other Liabilities	0
Other Net Income	765
Property and Equipment	19
Research and Development	13,140
Revenues	0
Selling, General and Administrative Expense	6,246

Output Variable	Value in 1000 USD
Assets	23,340
Liabilities	6,199
Expenses	44,689
Stockholders Equity	17,141
Net Income	-43,924
Comprehensive Net Income	-55
Economic Capital Ratio	126%

